222 related articles for article (PubMed ID: 25380840)
1. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
2. GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells.
Fang L; Gao L; Xie L; Xiao G
Oncol Rep; 2018 Mar; 39(3):1283-1291. PubMed ID: 29286162
[TBL] [Abstract][Full Text] [Related]
3. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
4. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.
Wang X; Jiang R; Cui EH; Feng WM; Guo HH; Gu DH; Tang CW; Xue T; Bao Y
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1244-50. PubMed ID: 27097942
[TBL] [Abstract][Full Text] [Related]
5. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.
Liu Y; Xue F; Zhang Y; Lei P; Wang Z; Zhu Z; Sun K
Anticancer Drugs; 2017 Nov; 28(10):1097-1105. PubMed ID: 28885268
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells.
Xu GD; Shi XB; Sun LB; Zhou QY; Zheng DW; Shi HS; Che YL; Wang ZS; Shao GF
J Zhejiang Univ Sci B; 2013 Jun; 14(6):460-7. PubMed ID: 23733422
[TBL] [Abstract][Full Text] [Related]
7. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.
Yang J; Yu H; Shen M; Wei W; Xia L; Zhao P
Cancer Sci; 2014 Feb; 105(2):219-27. PubMed ID: 24262005
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
Tang DJ; Dong SS; Ma NF; Xie D; Chen L; Fu L; Lau SH; Li Y; Li Y; Guan XY
Hepatology; 2010 Apr; 51(4):1255-63. PubMed ID: 20112425
[TBL] [Abstract][Full Text] [Related]
9. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
[TBL] [Abstract][Full Text] [Related]
11. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.
Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN
Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999
[TBL] [Abstract][Full Text] [Related]
12. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
13. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
14. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W
Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525
[TBL] [Abstract][Full Text] [Related]
15. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
[TBL] [Abstract][Full Text] [Related]
16. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
17. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
18. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
[TBL] [Abstract][Full Text] [Related]
19. Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.
Wang J; Chen Y; Xiang F; Li M; Li H; Chi J; Ren K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1505-1512. PubMed ID: 28918673
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
